Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.
Thiogenesis Therapeutics Corp announced the approval of a grant of 400,000 common share purchase options to two directors, exercisable at $0.77, under the company’s Omnibus Equity Incentive Plan. This strategic move is likely aimed at aligning the interests of the directors with the company’s long-term goals, potentially impacting its operational dynamics and market positioning positively.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. The company is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S. It focuses on developing sulfur-containing prodrugs that serve as precursors to thiol-active compounds, aiming to treat serious pediatric diseases with unmet medical needs. Their lead product candidate, TTI-0102, is in a Phase 2 clinical trial for Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) and plans to initiate trials for Leigh syndrome, Rett syndrome, and pediatric MASH.
Average Trading Volume: 32,749
Technical Sentiment Signal: Buy
Current Market Cap: C$32.41M
See more insights into TTI stock on TipRanks’ Stock Analysis page.